Werewolf Therapeutics
HOWL
73 hedge funds and large institutions have $41.7M invested in Werewolf Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 14 reducing their positions, and 8 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
6% more funds holding
Funds holding: 69 → 73 (+4)
8% more call options, than puts
Call options by funds: $43K | Put options by funds: $40K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10.46% less ownership
Funds ownership: 73.7% → 63.24% (-10%)
39% less capital invested
Capital invested by funds: $68.3M → $41.7M (-$26.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$170K |
| 2 |
BlackRock
New York
|
+$129K |
| 3 |
LCS
Levin Capital Strategies
New York
|
+$102K |
| 4 |
JP Morgan Chase
New York
|
+$101K |
| 5 |
Jane Street
New York
|
+$80.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.24M |
| 2 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
-$1.48M |
| 3 |
Millennium Management
New York
|
-$1.48M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.01M |
| 5 |
Two Sigma Advisers
New York
|
-$239K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EGM
76
Engineers Gate Manager
New York
| – | -$25K | -11,777 | Closed |
|
77
Citadel Advisors
Miami,
Florida
| – | -$23.5K | -11,507 | Closed |
|
|
PD
78
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$808 | -381 | Closed |
|
79
Russell Investments Group
London,
United Kingdom
| – | -$182 | -86 | Closed |
|
|
CPA
80
Capital Performance Advisors
Walnut Creek,
California
| – | -$127 | -60 | Closed |
|
81
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$234 | +115 | +60% |
|
HOWL Hedge Fund Activity: Q4 2024 in Review
73 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q4 2024, worth a combined $41.7M — down 39% from $68.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new HOWL positions and 8 closed out — a net gain of 4 holders — while 29 added to existing stakes and 14 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $170K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $4.24M sold.
- 73 institutional investors held Werewolf Therapeutics (HOWL) as of Q4 2024, up from 69 in Q3 2024.
- Funds reported $41.7M of Werewolf Therapeutics stock for Q4 2024, down 39% quarter-over-quarter.
- 12 funds opened new Werewolf Therapeutics positions in Q4 2024 and 8 closed out, a net change of +4 holders.
- The largest Werewolf Therapeutics buyer in Q4 2024 was Deutsche Bank, an estimated $170K added.
- The largest Werewolf Therapeutics seller in Q4 2024 was Adage Capital Partners, an estimated $4.24M sold.
Based on aggregated 13F filings for Q4 2024.